# Gecacitinib for cGVHD: Safety and Efficacy in Patients After ≥2 Lines of Prior Therapy

> **NCT07012304** · PHASE1,PHASE2 · RECRUITING · sponsor: **Yujun DONG** · enrollment: 24 (estimated)

## Conditions studied

- Chronic Graft Versus Host Disease

## Interventions

- **DRUG:** Gecacitinib Hydrochloride Tablets

## Key facts

- **NCT ID:** NCT07012304
- **Lead sponsor:** Yujun DONG
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-30
- **Primary completion:** 2027-02-28
- **Final completion:** 2029-02-28
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07012304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07012304, "Gecacitinib for cGVHD: Safety and Efficacy in Patients After ≥2 Lines of Prior Therapy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07012304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*